Small Cell Lung Cancer: A New Era Is Beginning?
Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positi...
Сохранить в:
| Формат: | Online |
|---|---|
| Язык: | английский |
| Опубликовано: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Предметы: | |
| Online-ссылка: | ONIX_20220111_9783036523019_772 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|
| _version_ | 1869514528957399040 |
|---|---|
| collection | Directory of Open Access Books |
| description | Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positive results in terms of improvement of overall survival obtained with a combination of checkpoint inhibitors (atezolizumab or durvalumab) with platinum-etoposide in patients with extensive disease. Moreover, nivolumab and pembrolizumab showed antitumor activity and received U.S. FDA approval as single agents in patients pretreated with platinum-based therapy and at least one other therapy. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly (ADP-ribose) polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody–drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approached for limited disease. This Special Issue will highlight the current state of treatment of extensive SCLC, focusing on the biology of SCLC, immune-checkpoint inhibitors, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques. |
| format | Online |
| id | doab-20.500.12854ir-76940 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-769402024-03-30T23:21:38Z Small Cell Lung Cancer: A New Era Is Beginning? Morabito, Alessandro Rolfo, Christian immune checkpoint inhibitors extensive-stage small cell lung cancer nivolumab ipilimumab pembrolizumab atezolizumab durvalumab chemotherapy small-cell lung cancer lobectomy pneumonectomy radiotherapy multimodal treatment immunotherapy SCLC PARP DDR ICB synthetic lethality SLFN11 STING pathology and classification of SCLC biology of SCLC immune-checkpoint inhibitors in SCLC small cell lung cancer Immunotherapy extensive disease lurbinectedin gene pathway pathobiology targeted therapy circulating tumor cells prognostic biomarker targeted agents n/a thema EDItEUR::M Medicine and Nursing Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positive results in terms of improvement of overall survival obtained with a combination of checkpoint inhibitors (atezolizumab or durvalumab) with platinum-etoposide in patients with extensive disease. Moreover, nivolumab and pembrolizumab showed antitumor activity and received U.S. FDA approval as single agents in patients pretreated with platinum-based therapy and at least one other therapy. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly (ADP-ribose) polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody–drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approached for limited disease. This Special Issue will highlight the current state of treatment of extensive SCLC, focusing on the biology of SCLC, immune-checkpoint inhibitors, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques. 2022-01-11T13:47:07Z 2022-01-11T13:47:07Z 2021 book ONIX_20220111_9783036523019_772 9783036523019 9783036523026 https://directory.doabooks.org/handle/20.500.12854/76940 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4531 https://mdpi.com/books/pdfview/book/4531 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-2302-6 10.3390/books978-3-0365-2302-6 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036523019 9783036523026 150 Basel, Switzerland open access |
| spellingShingle | immune checkpoint inhibitors extensive-stage small cell lung cancer nivolumab ipilimumab pembrolizumab atezolizumab durvalumab chemotherapy small-cell lung cancer lobectomy pneumonectomy radiotherapy multimodal treatment immunotherapy SCLC PARP DDR ICB synthetic lethality SLFN11 STING pathology and classification of SCLC biology of SCLC immune-checkpoint inhibitors in SCLC small cell lung cancer Immunotherapy extensive disease lurbinectedin gene pathway pathobiology targeted therapy circulating tumor cells prognostic biomarker targeted agents n/a thema EDItEUR::M Medicine and Nursing Small Cell Lung Cancer: A New Era Is Beginning? |
| title | Small Cell Lung Cancer: A New Era Is Beginning? |
| title_full | Small Cell Lung Cancer: A New Era Is Beginning? |
| title_fullStr | Small Cell Lung Cancer: A New Era Is Beginning? |
| title_full_unstemmed | Small Cell Lung Cancer: A New Era Is Beginning? |
| title_short | Small Cell Lung Cancer: A New Era Is Beginning? |
| title_sort | small cell lung cancer a new era is beginning |
| topic | immune checkpoint inhibitors extensive-stage small cell lung cancer nivolumab ipilimumab pembrolizumab atezolizumab durvalumab chemotherapy small-cell lung cancer lobectomy pneumonectomy radiotherapy multimodal treatment immunotherapy SCLC PARP DDR ICB synthetic lethality SLFN11 STING pathology and classification of SCLC biology of SCLC immune-checkpoint inhibitors in SCLC small cell lung cancer Immunotherapy extensive disease lurbinectedin gene pathway pathobiology targeted therapy circulating tumor cells prognostic biomarker targeted agents n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | immune checkpoint inhibitors extensive-stage small cell lung cancer nivolumab ipilimumab pembrolizumab atezolizumab durvalumab chemotherapy small-cell lung cancer lobectomy pneumonectomy radiotherapy multimodal treatment immunotherapy SCLC PARP DDR ICB synthetic lethality SLFN11 STING pathology and classification of SCLC biology of SCLC immune-checkpoint inhibitors in SCLC small cell lung cancer Immunotherapy extensive disease lurbinectedin gene pathway pathobiology targeted therapy circulating tumor cells prognostic biomarker targeted agents n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20220111_9783036523019_772 |